Wellness Study

INTERVENTION: 0.05mg escitalopram oxalate in a lactose base in an opaque capsule. 1 capsule taken daily via oral route for a period of 6 weeks. CONDITION: Chronic illness ‐ patients who are generally unwell for an extended period. PRIMARY OUTCOME: Reduction in anxiety assessed by Spielberger Questionnaire and Hospital Anxiety and Depression (HAD) Scale. Reduction in fatigue assessed by Fatigue Assessment Scale. SECONDARY OUTCOME: Increase in effort tolerance as assessed by the Medical Research Council (MRC) Dyspnoea Scale. INCLUSION CRITERIA: Chronic illness ‐ patients who are generally unwell for an extended period.